Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+34.28%
+6.50%
-6.76%
+1.93%
+1.43%
CYTK
Cytokinetics Incorpo
$56.97
Login to see Cytokinetics Incorpo (CYTK) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Upgraded on attractively valued
Earnings are forecast to grow
Technical Indicators
5+ Days Up
Chart
$51.5 (+10.62%)
$38.58 (+47.67%)
$30.14 (+89.02%)
$54.97 (+3.64%)
CYTK has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
CYTK overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
CYTK Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
CYTK Street view is bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayCYTK Earnings
The TTM reflects 12-month period, providing review of CYTK financial performance.
The company financial health has shown minor improvement, but significant issues remain
Financial Score
What is CYTK current stock price?
What are CYTK stock strengths?
What risks are associated with CYTK stock?
When is CYTK next earnings report?
What is CYTK market cap and volume?
What is CYTK's current Stock IQ?
Should I buy CYTK stock right now?
Is CYTK a Strong Buy right now?
What does a 'Strong Buy' rating mean for CYTK?
What does a 'Strong Sell' rating mean for CYTK?
What factors influence CYTK's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+34.28%
+6.50%
-6.76%
+1.93%
+1.43%
CYTK
Cytokinetics Incorpo
Current Price
$56.97
Stock Insights
Strengths
Upgraded on attractively valued
Earnings are forecast to grow
Technical Indicators
5+ Days Up
Login to unlock Cytokinetics Incorpo (CYTK) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$51.5 (+10.62%)
$38.58 (+47.67%)
$30.14 (+89.02%)
$54.97 (+3.64%)
CYTK Analysts Opinion
CYTK Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
CYTK Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
CYTK Street view is bullish and have positive views on the near-term outlook
CYTK has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Average key support and resistance price levels.
Login to displayCYTK Earnings
The TTM data reflects the most recent 12-month period, providing overview of CYTK financial performance.
CYTK Financial Health
The company financial health has shown minor improvement, but significant issues remain
Financial Score
CYTK Latest Analysis
B of A Securities Maintains Cytokinetics (CYTK) Neutral Recommendation. Fintel reports that on October 2 2025 B of A Securities maintained coverage of Cytokinetics (NasdaqGS:CYTK) with a Neutral recommendation. Analyst Price Forecast Suggests 37.42% Upside
Today
Can CYTK Clinch a Potential FDA Nod for Its Cardiovascular Drug?. Cytokinetics aficamten shows superiority over metoprolol in late-stage oHCM trial boosting investor confidence despite FDA delay.
Thu Oct 2, 2025
HC Wainwright & Co. Reiterates Cytokinetics (CYTK) Buy Recommendation. Fintel reports that on September 29 2025 HC Wainwright &. Co. reiterated coverage of Cytokinetics (NasdaqGS:CYTK) with a Buy recommendation. Analyst Price Forecast Suggests 43.01% Upside
Tue Sep 30, 2025
Cytokinetics stock maintains Buy rating as H.C. Wainwright cites exercise data.
Tue Sep 30, 2025
Class Action Filed Against Cytokinetics Incorporated (CYTK) - November 17 2025 Deadline to Join - Contact Levi &. Korsinsky. NEW YORK Sept. 26 2025 /PRNewswire/ -- Levi & Korsinsky LLP notifies investors in Cytokinetics Incorporated (Cytokinetics or the Company) (NASDAQ: CYTK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cytokinetics investors...
Fri Sep 26, 2025
Cytokinetics Announces Call for Proposals for Its Eighth Annual Communications Grant Program. Program to Provide Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular Diseases
Wed Sep 24, 2025
Cytokinetics to Present at the Stifel 2025 Virtual Cardiometabolic Forum. ) today announced that members of the Company'.s management team are scheduled to present a corporate update at the Stifel 2025 Virtual Cardiometabolic Forum on Tuesday September 30 2025 at 10:00 AM Eastern Time.. The webcast replay will be archived on the Cytokinetics website for 90 days following the conclusion of the event.aficamten a cardiac myosin inhibitor following positive results from SEQUOIA-HCM the pivotal P
Tue Sep 23, 2025
Cytokinetics (CYTK) Drops on $650-Million Debt Issuance.
Thu Sep 18, 2025
Cytokinetics announces pricing of upsized $650M senior notes offering.
Wed Sep 17, 2025
Cytokinetics announces private placement of $550M convertible senior notes.
Tue Sep 16, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
CYTK Stock trends
CYTK Stock performance
CYTK Stock analysis
CYTK investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings